Company intelligence / Profile preview

MidaSol Therapeutics

Oxford, United Kingdom

Ownership: Private
Development stage: Other

Overview

Phase IIa clinical studies with MidaForm insulin PharmFilm were expected to report results in the second half of 2014[2]. The joint venture announced positive Phase 1 clinical results for insulin-passivated gold glyconanoparticles formulated into PharmFilm for buccal delivery[9].

Therapeutic areas: Endocrinology
Modalities: NanoparticleFilm-based drug delivery
Industry: Biotech

Drug pipeline

1 asset

Midaform insulin

Unknown

Partnerships

Midatech Ltd[1]MonoSol Rx LLC[1]Major US pharmaceutical company (unnamed, under research collaboration agreement)[4]

Beyond the preview

Go deeper on MidaSol Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MidaSol Therapeutics.

Explore the full profile